# Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B

> **NCT03349008** · PHASE4 · UNKNOWN · sponsor: **Cttq** · enrollment: 480 (estimated)

## Conditions studied

- Chronic Hepatitis b
- Liver Inflammation

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Magnesium Isoglycyrrhizinate
- **DRUG:** Diammonium Glycyrrhizinate
- **DRUG:** Magnesium Isoglycyrrhizinate Placebo
- **DRUG:** Diammonium Glycyrrhizinate Placebo

## Key facts

- **NCT ID:** NCT03349008
- **Lead sponsor:** Cttq
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-25
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03349008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03349008, "Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03349008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*